BioSpace News Archive

Mustang Bio, Inc. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,588,236 of its shares of common stock at a purchase price of $1.70 per share in a registered direct offering priced at-the-market under Nasdaq rules.

Woebot Health today announced positive results from a study at Children’s Hospital of The King’s Daughters (CHKD) showing that the digital mental health intervention W-GenZD, a Woebot-based study app, led to reductions in depressive symptoms that were non-inferior to those achieved by a clinician-led telehealth Cognitive Behavioral Therapy (CBT) skills group.

Edwards Lifesciences Corporation announced successful results from TRISCEND II, a randomized controlled pivotal trial designed to evaluate the safety and effectiveness of the groundbreaking EVOQUE tricuspid valve replacement system with optimal medical therapy compared to OMT alone with 2:1 randomization.

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced today 510(k) clearance of its new 3D-printed tibial implants, the Vantage® Ankle 3D and 3D+.

Moderna, Inc. announced it was ranked as one of the top employers in the global biopharmaceutical industry in Science and Science Careers’ 2023 Top Employers Survey for the ninth consecutive year.

Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair therapies, as well as one-year results from the CLASP IID registry.

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2023 financial results and corporate highlights after the U.S. financial markets close on Thursday, November 2, 2023.

RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter 2023 after the market close on Thursday, November 9, 2023.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that announced that it will report the Company’s third quarter 2023 financial results on Thursday, November 2, 2023, after the close of the U.S. financial markets.

IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 third quarter financial results before the market opens on Friday, November 3rd.